Therapeutic agent

Creatine

PreliminaryEvidence level
1Registered trials
1Conditions
0Study references

Evidence Summary

Evidence Level
Preliminary
Mechanism
Enrollment: Actual, Sponsor Type: Other, Unknown / General
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
Creatine monohydrate 5g daily. RCT evidence (d~1) for mental fatigue and concentration in PASC. Mitochondrial support. Safe for most; monitor renal and fluid retention.

Clinical Trials

1 trial(s) registered

NCT IDTitlePhaseStatus
NCT02374112Creatine Supplementation in Chronic Fatigue SyndromeNot applicableActive, not recruiting

Key Studies / References

  • See linked studies